Trimetrexate

CHEMBL119 Phase 4 Zugelassen Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

369.4 g/mol

LogP

2.5

Phase

4

Trimetrexate is a lipophilic antifolate that inhibits dihydrofolate reductase (DHFR), blocking tetrahydrofolate synthesis required for DNA replication, thereby exerting cytotoxic effects on rapidly dividing cells. It was used as an alternative treatment for Pneumocystis jirovecii pneumonia in immunocompromised patients and investigated as an antineoplastic agent in colorectal cancer and leukemia. It requires leucovorin rescue to protect normal host cells.

Molekularmasse

369,4000 g/mol

LogP

2,50

TPSA

118,00 Å²

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Pancreatic Cancer Lymphoma Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D-Struktur

SVG PNG

Cite this structure

Embed this structure

SMILES

COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC

InChI

InChI=1S/C19H23N5O3/c1-10-11(5-6-13-16(10)18(20)24-19(21)23-13)9-22-12-7-14(25-2)17(27-4)15(8-12)26-3/h5-8,22H,9H2,1-4H3,(H4,20,21,23,24)

Molecular Formula

C19H23N5O3

HBD / HBA

3 / 8

Rotierbare Bindungen

6

Schwere Atome

27

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

Trimetrexate is a lipophilic antifolate that inhibits dihydrofolate reductase (DHFR), blocking tetrahydrofolate synthesis required for DNA replication, thereby exerting cytotoxic effects on rapidly dividing cells. It was used as an alternative treatment for Pneumocystis jirovecii pneumonia in immunocompromised patients and investigated as an antineoplastic agent in colorectal cancer and leukemia. It requires leucovorin rescue to protect normal host cells.

Yes, Trimetrexate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL119. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5583. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Trimetrexate auf PillFYI

Struktur

Schnelldaten

Formel: C19H23N5O3

Externe Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.